Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma.
about
A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanomaRandomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic MelanomaNivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy.Monitoring immune-checkpoint blockade: response evaluation and biomarker development.Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy.Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.Efficacy and toxicity of transarterial chemoembolization therapy using cisplatin and gelatin sponge in patients with liver metastases from uveal melanoma in an Asian population.Nivolumab in melanoma.Pembrolizumab use for the treatment of advanced melanoma.Biomarkers to predict prognosis and response to checkpoint inhibitors.Two cases of melanomas paradoxically metastasizing to the intestinal tract during nivolumab therapy.Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab.Usefulness of serum 5-S-cysteinyl-dopa as a biomarker for predicting prognosis and detecting relapse in patients with advanced stage malignant melanoma.Impact of the Tumor Microenvironment on Tumor-Infiltrating Lymphocytes: Focus on Breast Cancer.Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers.Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.Harnessing the heart's resistance to malignant tumors: cardiac-derived extracellular vesicles decrease fibrosarcoma growth and leukemia-related mortality in rodents.Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer.Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors.Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices.Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease.FKBP51s signature in peripheral blood mononuclear cells of melanoma patients as a possible predictive factor for immunotherapy.Emerging biomarkers for cancer immunotherapy in melanoma.Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients.Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma.Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial.Association of Inflammatory Markers with Disease Progression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors.The experience of immune checkpoint inhibitors in Chinese patients with metastatic melanoma: a retrospective case series.Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations.Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis.Melanoma Immunotherapy: Next-Generation Biomarkers.Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions.TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma.Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and BeyondPrognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New EvidencesmTOR, metabolism, and the immune response in HPV-positive head and neck squamous cell cancerKiller immunoglobulin-like receptor genotype did not correlate with response to anti-PD-1 antibody treatment in a Japanese cohort
P2860
Q33775322-82F9D2E3-24F6-48E3-911A-FA6C9A1FD379Q36027584-ACD03E3E-DF47-4999-8FE3-20297A07D05BQ37718376-D07CFDED-B5DC-43C0-A9B8-9EEFC24EE662Q38666241-B52FDB68-144A-47C5-B094-BBDE853F8BF3Q38672084-5B681771-57B0-4E9B-94DA-ED08D9EA7AE6Q38754614-B0DA1146-9BE2-41A8-82CC-C2E2840D2DEAQ38987724-454F3C73-594B-47C5-B33F-79297337816EQ38989508-B4C99B33-9F66-40FA-A2B8-41C32CB2537DQ39190201-22A56D03-9986-43AA-8ACD-99F444A2120CQ39223657-4AA90B4E-1E2E-45D9-AE02-CF0140419B5CQ40065192-8FC679C2-923A-4EFB-823F-C35392E11CF5Q40506025-5E7540F0-4562-4251-9CFF-365410C1C962Q40512287-798ED262-A51D-41EA-B7A1-25A73413134DQ41810793-19BF0415-9D2E-4759-A207-E1E3C9CA1581Q41899044-196918AE-03AE-4C1C-832D-4AE1AD276C74Q42369277-6A39D74D-3E83-4E37-A7D3-AFB33DD6937BQ47104850-DFD65A01-3D0E-43B7-99FA-5EB8B1E5362CQ47142109-A9FB6B1D-7FA5-4387-95FE-8FB75C01665DQ47151168-46DFEA6E-D5CD-4170-914B-B8C8F2636892Q47290990-253457DE-AA0F-41BE-A2A0-6EE37CE1B96CQ47999192-E75A5C59-7B82-4B1B-B1D0-4EC69ABC6098Q48244625-FC41BADA-83F7-4079-B213-843EBA442900Q50058145-2D9E5E06-61C0-4FCE-8CFB-87AD5B053B9BQ50074196-1B3B01F5-6017-4B40-BE76-D91D12753270Q50104370-6FA69340-39B5-461C-B473-2AA815AF3E0DQ50609075-1D4695A0-EDE6-49D0-8C51-6036E1728D2DQ50736853-7A2BD384-D633-4389-A46E-E9B1317D0B74Q51529309-AD5D0C86-79B8-4C69-AAD1-C0DEB25FD710Q52721746-95D713BC-A60F-45D5-BB4D-9AEF58E06C82Q52774997-B170A1BF-7C51-4914-A896-2E08E164FBA5Q52888037-44073DA5-2E6B-4DA7-AF58-26AA92D1C7A6Q54960920-D5F9D29A-C9DD-4141-9C96-3F5999D6A433Q55136811-8FFAF8C7-92AE-4A6B-8261-3740CC60E247Q55156734-970BB71F-DC9A-4EA7-A428-57DEF6057258Q55287125-FAD3BC1A-AD30-4883-A0BE-81C9DB3CD0FDQ55378109-F5DD2D0A-1535-4D0C-9281-E06DF1B87D87Q56891609-8D24A42B-2FC7-45B5-93D0-EAF031219845Q57191808-77621BAA-61CB-4FBC-A9F5-81C1D96ECA7DQ57450687-2CB0D9A6-B85D-4E64-B92F-3634D7B2D7C2Q58107239-3971E993-6BDB-4F65-9170-70E447B0E795
P2860
Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Serum lactate dehydrogenase as ...... herapy in metastatic melanoma.
@ast
Serum lactate dehydrogenase as ...... herapy in metastatic melanoma.
@en
type
label
Serum lactate dehydrogenase as ...... herapy in metastatic melanoma.
@ast
Serum lactate dehydrogenase as ...... herapy in metastatic melanoma.
@en
prefLabel
Serum lactate dehydrogenase as ...... herapy in metastatic melanoma.
@ast
Serum lactate dehydrogenase as ...... herapy in metastatic melanoma.
@en
P2093
P2860
P356
P1476
Serum lactate dehydrogenase as ...... therapy in metastatic melanoma
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.2015.467
P407
P577
2016-01-21T00:00:00Z